Lung　adenocarcinoma　(LUAD)　is　the　most　common　histological　subtype　of　non-small　cell　lung　cancer,　but　novel　biomarkers　for　early　diagnosis　are　lacking.　Extensive　effort　has　been　exerted　to　identify　miRNA　biomarkers　in　LUAD.　Unfortunately,　high　inter-lab　variability　and　small　sample　sizes　have　produced　inconsistent　conclusions　in　this　field.　To　resolve　the　above-mentioned　limitations,　we　performed　a　comprehensive　analysis　based　on　LUAD　miRNome　profiling　studies　using　the　robust　rank　aggregation　(RRA)　method.　Moreover,　miRNA-gene　interaction　network,　pathway　enrichment　analysis　and　Kaplan-Meier　survival　curves　were　used　to　investigate　the　clinical　values　and　biological　functions　of　the　identified　miRNAs.　A　total　of　six　common　differentially　expressed　miRNAs　(DEMs)　were　identified　in　LUAD.　An　independent　cohort　further　confirmed　that　four　miRNAs　(miR-21-5p,　miR-210-3p,　miR-182-5p　and　miR-183-5p)　were　up-regulated　and　two　miRNAs　(miR-126-3p　and　miR-218-5p)　were　down-regulated　in　LUAD　tissues.　Pathway　enrichment　analysis　also　suggested　that　the　above-listed　six　DEMs　may　affect　LUAD　progression　via　the　estrogen　signaling　pathway.　Survival　analysis　based　on　the　TCGA　dataset　revealed　the　potential　prognostic　values　of　six　DEMs　in　patients　with　LUAD　(P-value＜0.01).　In　conclusion,　we　identified　a　panel　of　six　miRNAs　from　LUAD　using　miRNome　profiling　studies.　Our　results　provide　evidence　for　the　use　of　these　six　DEMs　as　novel　diagnostic　and　prognostic　biomarkers　for　LUAD　patients.